Antimicrobial Pharmacology in Critical Care

Quick Answer (30-Second Summary)

Critical illness fundamentally alters antimicrobial pharmacokinetics. Key principles:

• Beta-lactams exhibit time-dependent killing - target %T>MIC 50-100% (free drug). Extended or continuous infusions are superior in severe infections.
• Aminoglycosides are concentration-dependent - target Cmax/MIC 8-10. Once-daily dosing with therapeutic drug monitoring.
• Vancomycin targets AUC/MIC 400-600 mg.h/L (AUC-based monitoring per 2020 guidelines). Loading dose 25-35 mg/kg.
• Augmented renal clearance (ARC) affects 20-65% of ICU patients, requiring increased antibiotic doses.
• DALI study showed 31% of piperacillin and 16% of meropenem levels were subtherapeutic with standard dosing.
• Extended/continuous infusions of beta-lactams improve PK/PD target attainment and possibly clinical outcomes (BLING trials).

---

CICM Exam Focus

What Examiners Expect

First Part Written SAQ Topics:

• Mechanisms of action for each antimicrobial class
• PK/PD targets: time-dependent vs concentration-dependent killing
• Factors altering antimicrobial PK in critical illness (Vd, clearance, protein binding)
• Dosing optimization strategies (loading doses, extended infusions, TDM)
• Toxicity profiles and monitoring

First Part Viva Topics:

• "Discuss the pharmacology of beta-lactam antibiotics"
• "How does critical illness affect antibiotic dosing?"
• "Explain PK/PD targets for aminoglycosides vs beta-lactams"
• "What is augmented renal clearance and how does it affect antimicrobial dosing?"
• "Describe vancomycin dosing and monitoring in the ICU"

Common SAQ Stems:

• "A patient with septic shock is commenced on piperacillin-tazobactam. Describe the pharmacological basis for continuous infusion."
• "Outline the mechanism of action and PK/PD optimization of aminoglycosides."
• "Describe vancomycin pharmacokinetics and therapeutic drug monitoring targets."

---

Key Points (10 Must-Know Facts)

1. Time-dependent killing (beta-lactams): efficacy depends on duration above MIC (%T>MIC). Target 50-100% of dosing interval with free drug above MIC.

2. Concentration-dependent killing (aminoglycosides, fluoroquinolones): efficacy depends on peak concentration. Target Cmax/MIC 8-10 for aminoglycosides.

3. Augmented renal clearance (ARC): CrCl greater than 130 mL/min/1.73 m² in 20-65% of ICU patients. Increases clearance of renally-excreted antibiotics by 50-100%.

4. Vancomycin AUC-guided dosing: Target AUC/MIC 400-600 mg.h/L (2020 guidelines). AUC greater than 600 mg.h/L increases nephrotoxicity.

5. DALI study: 31% of piperacillin and 16% of meropenem trough levels were subtherapeutic in critically ill patients receiving standard dosing.

6. Loading doses are essential for hydrophilic antibiotics (aminoglycosides, beta-lactams, vancomycin) due to increased Vd in sepsis (2-3x normal).

7. Extended/continuous beta-lactam infusions improve PK/PD target attainment. BLING-II showed improved clinical cure; BLING-III showed no mortality benefit but improved secondary outcomes.

8. Beta-lactamase inhibitors (clavulanate, tazobactam, avibactam) protect beta-lactam ring from enzymatic hydrolysis. Some (avibactam) have activity against KPC carbapenemases.

9. Aminoglycoside toxicity is related to trough concentration and duration. Once-daily dosing reduces toxicity while maintaining efficacy through post-antibiotic effect.

10. Linezolid causes dose-dependent thrombocytopenia in 30-50% of ICU patients (higher than general ward populations). Monitor platelet count and limit duration to 14 days when possible.

---

Antimicrobial PK/PD Fundamentals

Classification by Killing Pattern

Antimicrobials exhibit three distinct killing patterns that determine optimal dosing strategies [1,2]:

Minimum Inhibitory Concentration (MIC)

MIC is the lowest concentration of an antimicrobial that inhibits visible growth of a microorganism after overnight incubation [3].

Clinical significance:

• Relates drug concentration to bacterial susceptibility
• Basis for all PK/PD targets
• Determined by broth microdilution (reference) or automated systems (Vitek, MicroScan)
• EUCAST and CLSI provide breakpoint interpretations

Limitations of MIC:

• Measured under optimal growth conditions (not in vivo)
• Single time-point measurement
• Does not account for protein binding
• May not predict in vivo activity (inoculum effect, biofilm)

---

Beta-Lactam Antibiotics

Mechanism of Action

Primary target: Penicillin-Binding Proteins (PBPs) [4,5]

Beta-lactams inhibit bacterial cell wall synthesis by binding to PBPs, which are transpeptidase enzymes involved in peptidoglycan cross-linking.

Mechanism:

1. Beta-lactam ring mimics D-Ala-D-Ala terminus of peptidoglycan precursor
2. Irreversible covalent binding to PBP active site (serine residue)
3. Inhibition of transpeptidation (cross-linking of peptidoglycan strands)
4. Weakened cell wall unable to resist osmotic pressure
5. Cell lysis (bactericidal activity during active growth phase)

PBP Classification:

• PBP1: Transpeptidase-transglycosylase (cell elongation)
• PBP2: Cell shape determination; target of mecillinam
• PBP3: Septum formation during cell division; primary target of piperacillin
• PBP2a: Altered PBP in MRSA with low beta-lactam affinity

Selectivity:

• PBPs are unique to bacteria (not present in mammalian cells)
• Selective toxicity: affects bacteria without harming host

Resistance Mechanisms

1. Beta-lactamase production (most common): Enzymatic hydrolysis of beta-lactam ring

   • Extended-spectrum beta-lactamases (ESBLs): Hydrolyze penicillins and cephalosporins
   • AmpC beta-lactamases: Chromosomal or plasmid-mediated; hydrolyze cephalosporins
   • Carbapenemases (KPC, NDM, OXA-48): Hydrolyze all beta-lactams

2. Altered PBPs: Mutations reducing beta-lactam affinity (PBP2a in MRSA)

3. Decreased permeability: Porin mutations limiting drug entry (Pseudomonas)

4. Efflux pumps: Active drug extrusion

Penicillins

Flucloxacillin pharmacokinetics [6]:

• Bioavailability: 50% (oral), 100% (IV)
• Protein binding: 95%
• Vd: 0.1 L/kg
• Clearance: Renal (70%) and hepatic (30%)
• Half-life: 0.5-1 hour
• Hepatotoxicity risk: 1 in 15,000 courses (cholestatic); higher with prolonged courses

Cephalosporins

Generations reflect spectrum evolution [7,8]:

Ceftriaxone pharmacokinetics [9]:

• Protein binding: 85-95% (concentration-dependent, lower at high doses)
• Vd: 0.12-0.18 L/kg
• Half-life: 6-9 hours (longest of cephalosporins - once daily dosing)
• Elimination: 60% renal, 40% biliary
• Caution: Ceftriaxone-calcium precipitation (avoid calcium-containing infusions)

Cefepime pharmacokinetics:

• AmpC-stable: Does not induce and is poor substrate for AmpC beta-lactamases
• Zwitterionic structure: Good Gram-negative penetration
• Neurotoxicity risk: Accumulates in renal failure; causes encephalopathy, seizures (PMID: 21217180) [10]

Carbapenems

Broadest spectrum beta-lactams - reserved for serious infections due to ESBLs, AmpC-producers [11,12].

Carbapenem resistance:

• KPC (Klebsiella pneumoniae carbapenemase): Class A serine carbapenemase
• NDM (New Delhi metallo-beta-lactamase): Class B metallo-enzyme; inhibited by EDTA
• OXA-48: Class D serine carbapenemase; endemic in certain regions

Meropenem PK in critical illness [13]:

• Vd increases 2-3× in sepsis (from 0.25 L/kg to 0.5-0.75 L/kg)
• ARC increases clearance by 30-50%
• Standard 1 g q8h achieves %T>MIC 40% in only 70% of patients with MIC 4 mg/L
• Solution: Extended (3-4 hour) or continuous infusion with loading dose

Beta-Lactamase Inhibitors

Protect beta-lactam ring from enzymatic hydrolysis [14,15]:

Avibactam: Novel mechanism - does NOT undergo hydrolysis; recyclable inhibitor. Active against Class A (including KPC) and Class C (AmpC) but NOT Class B metallo-beta-lactamases (NDM).

Time-Dependent Killing (%T>MIC)

Beta-lactam efficacy correlates with duration above MIC [16,17,18]:

PK/PD Target:

• Bacteriostatic effect: %fT>MIC 30-40%
• Maximal bactericidal effect: %fT>MIC 50-70%
• Optimal clinical efficacy: %fT>MIC 100% (for severe infections, immunocompromised)

Implications for dosing:

• Frequent dosing or prolonged infusions maintain concentrations above MIC
• Once-daily dosing inadequate for most beta-lactams
• Extended (3-4 hour) or continuous (24 hour) infusion optimizes %T>MIC

Monte Carlo simulations: Mathematical modeling predicting probability of target attainment (PTA) across range of MICs and patient populations [19].

---

Aminoglycosides

Mechanism of Action

Target: 30S ribosomal subunit [20,21]

Mechanism:

1. Energy-dependent uptake into bacterial cell
2. Binding to 16S rRNA component of 30S ribosomal subunit
3. Misreading of mRNA (incorporation of incorrect amino acids)
4. Production of aberrant proteins inserted into cell membrane
5. Increased membrane permeability → enhanced aminoglycoside uptake (self-enhancing)
6. Rapid bactericidal activity

Key features:

• Concentration-dependent killing
• Prolonged post-antibiotic effect (PAE): Continued suppression after drug levels fall below MIC
• Synergy with cell wall-active agents (penicillins, vancomycin) - enhanced uptake

Pharmacokinetics

Critical illness effects [22,23]:

• Vd increases 1.5-2× in sepsis (capillary leak, fluid resuscitation)
• Standard 5 mg/kg dose may not achieve target Cmax
• Increase loading dose to 7 mg/kg in severe sepsis
• ARC increases clearance - may need 8-10 mg/kg/dose

Once-Daily (Extended-Interval) Dosing

Rationale [24,25]:

1. Concentration-dependent killing: Higher peak = greater bacterial kill
2. Post-antibiotic effect: Continued suppression for 2-6 hours after drug cleared
3. Adaptive resistance: Bacteria become temporarily resistant after initial exposure; daily dosing allows susceptibility to recover
4. Reduced toxicity: Low trough concentrations minimize nephrotoxicity and ototoxicity

Dosing regimen:

• Gentamicin/Tobramycin: 5-7 mg/kg once daily
• Amikacin: 15-25 mg/kg once daily
• Adjust interval based on trough level or nomogram

Hartford Nomogram: Determines dosing interval (q24h, q36h, q48h) based on 6-14 hour random level [26]. Limitations in ICU: Not validated for ARC, obesity, burns, or CRRT.

Nephrotoxicity and Ototoxicity

Nephrotoxicity [27,28]:

• Incidence: 10-25% in critically ill patients
• Mechanism: Accumulation in proximal tubular cells → lysosomal dysfunction → apoptosis
• Risk factors: Prolonged therapy (greater than 7 days), elevated trough, concurrent nephrotoxins, AKI, hypovolemia
• Prevention: Once-daily dosing, maintain trough less than 1 mg/L, limit duration, avoid concurrent nephrotoxins

Ototoxicity:

• Cochlear (hearing loss) and vestibular (vertigo, ataxia)
• Often irreversible
• Mechanism: Hair cell destruction in cochlea and vestibular apparatus
• Risk factors: Prolonged therapy, high cumulative dose, concurrent loop diuretics, pre-existing hearing impairment
• Monitoring: Baseline and weekly audiometry if prolonged therapy

Therapeutic Drug Monitoring

Two-level approach (steady state):

• Peak (30 min post-infusion): Ensures adequate Cmax/MIC for efficacy
• Trough (pre-dose): Predicts toxicity risk

Single-level nomogram approach:

• Random level at 6-14 hours post-dose
• Plot on Hartford nomogram to determine interval

ICU considerations:

• Check levels after 2-3 doses (steady state in normal renal function)
• Recheck after any renal function change
• Bayesian dosing software increasingly used (DoseMeRx, InsightRX)

---

Glycopeptides (Vancomycin)

Mechanism of Action

Target: D-Ala-D-Ala terminus of peptidoglycan precursors [29,30]

Mechanism:

1. Binding to terminal D-Ala-D-Ala of lipid II (peptidoglycan precursor)
2. Steric hindrance preventing transglycosylation and transpeptidation
3. Inhibition of cell wall synthesis
4. Bactericidal activity (slowly - concentration and time-dependent)

Spectrum:

• Gram-positive only (too large to penetrate Gram-negative outer membrane)
• MRSA, coagulase-negative staphylococci, Enterococcus (except VRE), Streptococci, Clostridium difficile (oral)

Vancomycin-Resistant Enterococcus (VRE):

• VanA: Acquired; D-Ala-D-Lac substitution; high-level resistance (MIC greater than 64 mg/L); resistant to teicoplanin
• VanB: Acquired; D-Ala-D-Lac; moderate resistance; teicoplanin susceptible
• VanC: Intrinsic in E. gallinarum/casseliflavus; D-Ala-D-Ser; low-level resistance

Pharmacokinetics

Loading dose rationale [31]:

• Higher Vd in critical illness delays therapeutic levels
• Without loading dose: 2-3 days to reach steady state
• Loading dose: 25-35 mg/kg actual body weight (max 3,000 mg in obesity)
• Achieves therapeutic levels within hours

AUC/MIC-Guided Dosing (2020 Guidelines)

Paradigm shift from trough-based to AUC-based monitoring [32,33]:

Target: AUC/MIC 400-600 mg.h/L (assuming MIC 1 mg/L)

Rationale:

1. Trough concentrations (15-20 mg/L) are poor surrogates for AUC
2. Trough-based dosing often results in AUC greater than 600 mg.h/L → nephrotoxicity
3. AUC-guided dosing reduces AKI by up to 50% without compromising efficacy

Methods for AUC calculation:

1. Bayesian Software (Preferred):

   • DoseMeRx, InsightRX, Precise-PK
   • Uses population PK models (Goti, Udy ICU models)
   • Requires 1-2 levels (not necessarily at steady state)
   • Accounts for changing renal function dynamically
   • Provides probability of target attainment

2. Two-Level Pharmacokinetic Approach:

   • Peak (1-2 hours post-infusion) and trough (pre-dose)
   • Calculate Vd and CL using Sawchuk-Zaske method
   • AUC = Dose / CL
   • Less accurate with fluctuating renal function

Vancomycin-Associated Nephrotoxicity

Risk factors [34,35]:

• AUC greater than 600 mg.h/L (primary driver)
• Concurrent nephrotoxins (aminoglycosides, NSAIDs, IV contrast, amphotericin B, piperacillin-tazobactam)
• Prolonged therapy (greater than 7 days)
• ICU admission and severity of illness
• Baseline renal impairment
• Obesity

Piperacillin-tazobactam + vancomycin synergistic nephrotoxicity:

• Meta-analyses suggest increased AKI risk compared to vancomycin alone or with other beta-lactams
• Mechanism unclear; possibly related to drug interactions or different patient populations
• Consider cefepime or meropenem as alternative if appropriate spectrum [36]

Dosing in Special Populations

Augmented Renal Clearance (ARC):

• CrCl greater than 130 mL/min: Standard doses result in subtherapeutic AUC
• May require 30-35 mg/kg/day in divided doses (4-5 g/day in some patients)
• Frequent TDM essential [37]

Obesity:

• Use actual body weight for loading dose (25-35 mg/kg, cap at 3,000 mg)
• Vd increases proportionally with weight
• May require higher total daily doses
• AUC-guided monitoring critical [38]

CRRT:

• Significant extracorporeal clearance (30-50% depending on modality)
• Increased dosing typically required
• Loading dose unchanged; maintenance increases
• CVVHDF: 15-20 mg/kg loading, then 10-15 mg/kg q12h (adjust by TDM) [39]

---

Fluoroquinolones

Mechanism of Action

Targets: DNA gyrase (Gram-negatives) and Topoisomerase IV (Gram-positives) [40,41]

Mechanism:

1. Inhibition of DNA gyrase (topoisomerase II) - essential for DNA supercoiling
2. Inhibition of topoisomerase IV - essential for chromosome separation
3. Formation of drug-enzyme-DNA complex
4. Double-strand DNA breaks
5. Rapid bactericidal activity

Spectrum evolution:

• 1st generation (nalidixic acid): Limited to urinary Gram-negatives
• 2nd generation (ciprofloxacin): Broad Gram-negative, atypicals, poor Gram-positive
• 3rd generation (levofloxacin): Enhanced Gram-positive (respiratory pathogens)
• 4th generation (moxifloxacin): Excellent Gram-positive including anaerobes

Pharmacokinetics

PK/PD Optimization

Concentration-dependent with AUC-dependence [42,43]:

• Gram-negative infections: AUC/MIC greater than 125 (target ratio)
• Gram-positive (pneumococcus): AUC/MIC greater than 30-40

ICU considerations:

• High Vd allows once-daily dosing
• Moxifloxacin: No renal dose adjustment (hepatic elimination)
• Ciprofloxacin: Reduce dose in severe renal impairment
• QT prolongation: All fluoroquinolones prolong QT; moxifloxacin greater than levofloxacin greater than ciprofloxacin

Adverse Effects and Contraindications

Musculoskeletal toxicity:

• Tendinopathy and tendon rupture (especially Achilles)
• Risk factors: Age greater than 60, concurrent corticosteroids, renal failure
• Cartilage toxicity in children (animal studies) - avoid in pregnancy and under 18 years

CNS toxicity:

• Seizures (especially with NSAIDs co-administration)
• Delirium, confusion in elderly

Cardiac toxicity:

• QT prolongation → Torsades de Pointes
• Avoid in patients with prolonged QT, hypokalemia, hypomagnesemia, or on other QT-prolonging drugs

Black Box Warning (FDA): Tendinopathy, peripheral neuropathy, CNS effects - reserve for serious infections when no alternatives [44].

---

Macrolides

Mechanism of Action

Target: 50S ribosomal subunit [45,46]

Mechanism:

1. Reversible binding to 23S rRNA of 50S ribosomal subunit
2. Blocking of peptidyl transferase activity and translocation
3. Inhibition of protein synthesis
4. Bacteriostatic activity (bactericidal at high concentrations)

Spectrum:

• Gram-positives: Streptococci, Staphylococci (resistance increasing)
• Atypical pathogens: Mycoplasma, Chlamydia, Legionella
• Some Gram-negatives: H. influenzae, M. catarrhalis, Bordetella pertussis

Comparative Pharmacology

Immunomodulatory Effects

Non-antimicrobial anti-inflammatory properties [47,48]:

1. Neutrophil modulation: Reduced oxidative burst, decreased neutrophil recruitment
2. Cytokine reduction: IL-8, IL-6, TNF-α downregulation
3. Mucus reduction: Decreased mucin secretion in airways
4. Biofilm disruption: Enhanced activity against Pseudomonas biofilms

Clinical applications:

• ARDS: Early azithromycin associated with reduced mortality in some observational studies
• CAP: Macrolide + beta-lactam reduces mortality compared to beta-lactam alone
• Bronchiectasis/cystic fibrosis: Long-term azithromycin reduces exacerbations
• Sepsis: Potential mortality benefit (observational data)

COVID-19: Initial enthusiasm not supported by RCTs (RECOVERY trial showed no benefit) [49].

Adverse Effects

• GI disturbance: Erythromycin greater than clarithromycin greater than azithromycin
• QT prolongation: All macrolides; azithromycin associated with cardiac death in high-risk patients
• Drug interactions: Erythromycin and clarithromycin inhibit CYP3A4 (warfarin, midazolam, tacrolimus, statins)
• Cholestatic hepatitis: Rare with erythromycin estolate

---

Linezolid (Oxazolidinones)

Mechanism of Action

Target: 50S ribosomal subunit - unique binding site [50,51]

Mechanism:

1. Binding to 23S rRNA at the peptidyl transferase center
2. Prevention of formation of 70S initiation complex
3. Inhibition of protein synthesis at earliest stage
4. Bacteriostatic activity (bactericidal for Streptococci)

Unique features:

• Novel mechanism: No cross-resistance with other protein synthesis inhibitors
• Active against MRSA, VRE (VanA and VanB), penicillin-resistant pneumococci
• Resistance rare (but increasing: cfr and optrA genes)

Pharmacokinetics

Implications:

• Oral-IV switch at same dose
• No dose adjustment for renal or hepatic impairment
• Good tissue penetration (lung, bone, CSF)

Clinical Use

Indications:

• MRSA infections (pneumonia, skin/soft tissue, bacteremia)
• VRE infections
• Penicillin-resistant Streptococcus pneumoniae
• Alternative to vancomycin (especially MRSA pneumonia - better lung penetration)

MRSA pneumonia: Linezolid associated with better clinical outcomes than vancomycin in some studies (ZEPHyR trial) possibly due to superior lung penetration [52].

Toxicity in ICU

Thrombocytopenia [53,54]:

• Incidence: 30-50% in ICU patients (higher than general ward)
• Mechanism: Myelosuppression (dose and duration-dependent)
• Risk factors: Duration greater than 14 days, baseline thrombocytopenia, renal impairment
• Monitoring: Platelet count twice weekly; discontinue if platelets less than 100 × 10⁹/L and declining

Other toxicities:

• Peripheral neuropathy: Prolonged therapy (greater than 4 weeks)
• Optic neuropathy: Rare but severe; can be irreversible
• Lactic acidosis: Mitochondrial toxicity; monitor lactate in prolonged use
• Serotonin syndrome: MAO inhibitor activity; caution with SSRIs, SNRIs, tramadol

Duration limit: Maximum 28 days generally recommended; ideally less than 14 days [55].

---

Antifungal Agents

Overview

Azoles

Mechanism: Inhibition of lanosterol 14-α demethylase (CYP51) → decreased ergosterol synthesis → membrane disruption [56].

Fluconazole:

• Excellent oral bioavailability (90%)
• CSF penetration 70-80%
• Spectrum: Candida albicans (first-line for candidemia), C. tropicalis, Cryptococcus
• Gaps: C. krusei (intrinsic resistance), C. glabrata (dose-dependent susceptibility), Aspergillus

Voriconazole:

• Extended spectrum including Aspergillus
• First-line for invasive aspergillosis
• TDM required: Target trough 2-5.5 mg/L
• Toxicities: Visual disturbances (30%), hepatotoxicity, neurotoxicity, skin cancer (prolonged use)
• CYP2C19 polymorphism affects metabolism

Drug interactions: Azoles inhibit CYP3A4, CYP2C9, CYP2C19 → interactions with tacrolimus, cyclosporine, warfarin, midazolam, opioids [57].

Echinocandins

Mechanism: Inhibition of β-(1,3)-D-glucan synthase → disruption of fungal cell wall (unique to fungi) [58].

Key features:

• Fungicidal against Candida, fungistatic against Aspergillus
• First-line for invasive candidiasis in critically ill (ESCMID guidelines)
• No dose adjustment for renal impairment
• Minimal drug interactions (not CYP substrate)

Limitations:

• No CNS penetration (large molecule, highly protein-bound)
• Inactive against Cryptococcus, endemic fungi, Fusarium
• Reduced activity against C. parapsilosis (lower affinity)

Amphotericin B

Mechanism: Binding to ergosterol in fungal membrane → pore formation → cell death [59].

Formulations:

• Conventional (deoxycholate): High nephrotoxicity (30-80%), infusion reactions
• Liposomal (AmBisome): Reduced nephrotoxicity (15-30%), preferred in ICU
• Lipid complex (Abelcet): Intermediate toxicity profile

Spectrum: Broadest of all antifungals - Candida (all species), Aspergillus, Cryptococcus, Mucormycosis (first-line), endemic fungi.

Nephrotoxicity:

• Mechanism: Renal vasoconstriction + direct tubular toxicity
• Prevention: Sodium loading (500 mL 0.9% saline before and after infusion), liposomal formulation
• Monitor: Creatinine, potassium, magnesium (wasting common)

Dosing:

• Conventional: 0.5-1.5 mg/kg/day (test dose often given)
• Liposomal: 3-5 mg/kg/day (higher doses for mucormycosis: 5-10 mg/kg)

---

PK/PD Optimization in the ICU

Altered Pharmacokinetics in Critical Illness

Volume of Distribution (Vd) Changes [60,61]:

Augmented Renal Clearance (ARC)

Definition: Creatinine clearance greater than 130 mL/min/1.73 m² [62,63]

Epidemiology:

• Prevalence: 20-65% of ICU patients
• Risk factors: Young age (less than 50), trauma, burns, sepsis (hyperdynamic phase), obesity, polytrauma

Mechanism:

• Hyperdynamic circulation → increased renal blood flow
• Fluid resuscitation → increased GFR
• Decreased serum creatinine may mask ARC

Clinical impact:

• Subtherapeutic antibiotic levels with standard dosing
• Udy et al. showed 60% of patients with ARC had subtherapeutic beta-lactam levels [64]

Management:

• Measure 8-hour urinary creatinine clearance (most accurate)
• Increase dose by 50-100% for renally-cleared antibiotics
• Consider continuous infusion for beta-lactams
• Frequent TDM for vancomycin and aminoglycosides

DALI Study

Defining Antibiotic Levels in Intensive Care Patients (DALI) [65,66]:

Design: Multinational prospective PK point-prevalence study in 68 ICUs across 10 countries.

Key findings:

• 16% of patients had undetectable beta-lactam concentrations at 50% of dosing interval
• 31% of piperacillin and 16% of meropenem levels were below MIC at mid-dosing interval
• Only 60% achieved 50% fT>MIC target; only 30% achieved 100% fT>MIC
• Subtherapeutic concentrations associated with treatment failure and mortality

Risk factors for subtherapeutic levels:

• ARC
• Hypoalbuminemia (increased free fraction → enhanced clearance)
• High severity of illness (SOFA score)
• Larger fluid balance

Implications:

• Standard beta-lactam dosing inadequate in critically ill
• Extended or continuous infusion improves target attainment
• TDM increasingly advocated (though not universally available)

---

Extended and Continuous Infusions

Rationale for Prolonged Infusion

Time-dependent antibiotics require sustained concentrations above MIC [67,68]:

Evidence Base

BLING-II Trial (Beta-Lactam Infusion Group) [69]:

• Multicenter RCT: Continuous vs intermittent infusion of piperacillin-tazobactam or meropenem in severe sepsis
• Primary outcome: 90-day survival - no significant difference
• Secondary outcomes: Higher clinical cure rate (56% vs 46%, p=0.02) with continuous infusion
• Higher proportion achieving target concentration with continuous infusion

BLING-III Trial [70]:

• Larger RCT (7,000+ patients) in severe sepsis
• Continuous vs intermittent piperacillin-tazobactam or meropenem
• Primary outcome: 90-day all-cause mortality - no significant difference
• Secondary outcomes: Reduced ICU duration, improved clinical cure with continuous infusion
• Interpretation: No mortality benefit but potential for clinical improvement

Meta-analyses:

• Modest mortality benefit with extended/continuous infusion (OR 0.74-0.85)
• Greater benefit in patients with higher severity of illness (APACHE II greater than 20)
• Most pronounced effect with high-MIC pathogens [71]

Practical Implementation

Loading dose is ESSENTIAL:

• Must achieve therapeutic concentrations before starting continuous infusion
• Loading dose calculated for increased Vd: Use 25-30 mg/kg for piperacillin

Stability considerations:

• Meropenem: Stable at room temperature for 6-8 hours (12 hours refrigerated)
• Piperacillin-tazobactam: Stable for 24 hours at room temperature
• Ceftazidime: Stable for 24 hours
• Prepare in normal saline (not dextrose for carbapenems)

Continuous infusion protocol (example - piperacillin-tazobactam):

1. Loading dose: 4.5 g over 30 minutes
2. Continuous infusion: 13.5 g over 24 hours (0.56 g/hour)
3. Dedicated central line recommended
4. Prepare fresh every 12-24 hours depending on stability data

---

Therapeutic Drug Monitoring

Which Drugs Require TDM in ICU?

Beta-Lactam TDM

Growing evidence for beta-lactam TDM in ICU [72,73]:

Benefits:

• Ensure PK/PD target attainment (%fT>MIC)
• Identify patients with subtherapeutic levels (ARC)
• Avoid toxicity (cefepime neurotoxicity in renal failure)

Practical challenges:

• Assays not widely available
• Turnaround time may limit utility
• No established therapeutic ranges for most agents
• Cost and complexity

Current approach:

• Consider TDM in high-risk patients: septic shock, ARC, obesity, CRRT
• Target: Trough greater than 4-8× MIC (for safety margin)
• Emerging: Bayesian dosing software integrating TDM results

---

Australian/New Zealand Context

Therapeutic Guidelines Australia (eTG Complete)

Key recommendations:

• First-line empiric therapy for hospital-acquired pneumonia: Piperacillin-tazobactam ± vancomycin
• Severe sepsis (community-acquired): Ceftriaxone + azithromycin (respiratory source); piperacillin-tazobactam (intra-abdominal)
• MRSA bacteremia: Vancomycin (AUC-guided) or daptomycin
• Candidemia: Echinocandin first-line (anidulafungin or caspofungin)

Australian Resistance Patterns

MRSA:

• Community-acquired MRSA (CA-MRSA) prevalence increasing
• Healthcare-associated MRSA remains problematic in ICU
• First-line: Vancomycin (AUC-guided) or linezolid for pneumonia

Extended-spectrum beta-lactamases (ESBL):

• E. coli, Klebsiella pneumoniae most common
• Treatment: Meropenem (serious infections) or piperacillin-tazobactam (if MIC less than or equal to 16 mg/L and not urinary source)

Carbapenem-resistant Enterobacteriaceae (CRE):

• Increasing in Australia; predominantly KPC and OXA-48
• Treatment: Ceftazidime-avibactam (KPC, OXA-48) or meropenem-vaborbactam
• NDM-producers require polymyxin-based regimens

PBS Listings and TGA Approvals

ANZICS Antimicrobial Stewardship

Core principles:

1. De-escalation: Narrow spectrum once susceptibilities known
2. Duration: Procalcitonin-guided discontinuation where appropriate
3. Source control: Drainage, debridement where indicated
4. TDM: Vancomycin and aminoglycosides routinely monitored
5. Audit: Regular review of prescribing patterns

Indigenous Health Considerations

Aboriginal and Torres Strait Islander Patients:

• Higher rates of severe infections (RHD, bronchiectasis, skin/soft tissue)
• Higher rates of renal disease affecting drug clearance
• Importance of family involvement in treatment decisions
• Health literacy considerations in TDM discussions
• Remote/rural challenges: Limited TDM availability, delayed results

Māori Patients (New Zealand):

• Whānau involvement in care decisions
• Higher rates of rheumatic heart disease and severe infections
• Consider cultural preferences regarding treatment
• Tikanga (cultural protocols) in medication discussions

Communication:

• Use professional interpreters
• Explain TDM and dosing changes in accessible terms
• Engage Aboriginal Health Workers/Liaison Officers

---

SAQ Practice Questions

SAQ 1: Beta-Lactam Pharmacology and Dosing Optimization (15 marks)

Question:

A 68-year-old man (85 kg) is admitted to ICU with severe community-acquired pneumonia complicated by septic shock. He has a measured creatinine clearance of 165 mL/min. He is commenced on piperacillin-tazobactam 4.5 g IV 6-hourly by intermittent infusion over 30 minutes.

a) Describe the mechanism of action of piperacillin (2 marks)

b) Explain time-dependent killing and the relevant PK/PD target for piperacillin (3 marks)

c) Describe THREE pharmacokinetic changes in this patient that would affect piperacillin dosing (3 marks)

d) Calculate whether standard dosing is likely to achieve the PK/PD target for an organism with MIC 16 mg/L. Show your reasoning. (4 marks)

e) Outline a dosing strategy to optimize piperacillin exposure in this patient (3 marks)

---

SAQ 1: Model Answer

a) Mechanism of action of piperacillin (2 marks)

Piperacillin is a beta-lactam antibiotic that:

• Inhibits penicillin-binding proteins (PBPs), particularly PBP3 which is involved in septum formation (1 mark)
• The beta-lactam ring mimics D-Ala-D-Ala terminus of peptidoglycan precursors, binding covalently to PBP active site
• This inhibits transpeptidation (cross-linking of peptidoglycan), weakening the bacterial cell wall
• Results in osmotic lysis and bactericidal activity during active bacterial growth (1 mark)

b) Time-dependent killing and PK/PD target (3 marks)

Time-dependent killing (1 mark):

• Efficacy depends on the duration that free (unbound) drug concentration exceeds the MIC
• Increasing concentration above MIC does not improve killing (saturable effect)
• No concentration-dependent killing or significant post-antibiotic effect

PK/PD target (2 marks):

• %fT>MIC: Percentage of dosing interval with free drug concentration above MIC
• Target for piperacillin: 50-60% for bacteriostatic effect; 100% for optimal bactericidal activity in severe infections
• fT = free (unbound) drug; piperacillin protein binding is 20-30%

c) Three pharmacokinetic changes (3 marks) (1 mark each)

1. Increased volume of distribution (Vd):

   • Capillary leak syndrome in septic shock
   • Fluid resuscitation expands extracellular compartment
   • Vd may increase from 0.2 L/kg to 0.4-0.6 L/kg
   • Implication: Lower peak concentrations with standard doses

2. Augmented renal clearance (ARC):

   • CrCl 165 mL/min indicates ARC (greater than 130 mL/min threshold)
   • Hyperdynamic circulation increases GFR
   • Implication: Faster clearance, shorter half-life, lower trough concentrations

3. Hypoalbuminemia (likely in septic shock):

   • Reduced protein binding increases free drug fraction
   • Variable effect: May increase tissue penetration but also enhances renal clearance
   • Overall: May exacerbate subtherapeutic free drug levels due to enhanced elimination

d) PK/PD target attainment calculation (4 marks)

Given information:

• Dose: 4.5 g (4 g piperacillin) q6h (dosing interval = 6 hours)
• MIC: 16 mg/L
• CrCl: 165 mL/min (ARC)
• Weight: 85 kg

Assumptions for calculation (1 mark):

• Vd in sepsis: Approximately 0.4 L/kg = 34 L
• Half-life in ARC: Approximately 1.5-2 hours (normal 3-4 hours, reduced by 50% in ARC)
• Protein binding: 25% (free fraction 75%)

Calculation (2 marks):

Peak concentration (after 30-min infusion):

• Cpeak = Dose / Vd = 4000 mg / 34 L = 118 mg/L
• Free peak = 118 × 0.75 = 88 mg/L

Trough concentration (using mono-exponential decay):

• Using half-life of 1.5 hours over 5.5 hours (time to trough after end of infusion)
• Number of half-lives = 5.5 / 1.5 = 3.7 half-lives
• Ctrough = 118 × (0.5)^3.7 = 118 × 0.08 = 9 mg/L
• Free trough = 9 × 0.75 = 7 mg/L

Target assessment (1 mark):

• Free trough (7 mg/L) is below MIC (16 mg/L)
• The patient is unlikely to achieve %fT>MIC of even 50%, let alone 100%
• Standard dosing will NOT achieve the PK/PD target

e) Dosing strategy to optimize piperacillin exposure (3 marks)

1. Loading dose (1 mark):

   • Give a loading dose of 4.5 g over 30 minutes to rapidly achieve therapeutic concentrations
   • Accounts for increased Vd in sepsis

2. Continuous infusion (1 mark):

   • After loading dose, infuse 18 g piperacillin-tazobactam over 24 hours (13.5-18 g/24h depending on MIC)
   • Continuous infusion maintains 100% fT>MIC at steady state
   • Alternative: Extended infusion over 3-4 hours each dose

3. Monitoring and adjustment (1 mark):

   • Consider beta-lactam TDM if available (target trough 4-8× MIC)
   • Monitor for clinical response, inflammatory markers
   • Reassess if renal function changes (ARC may resolve or AKI may develop)
   • Consider carbapenem if MIC is above achievable concentrations

---

SAQ 2: Vancomycin Pharmacology and AUC-Guided Dosing (15 marks)

Question:

A 55-year-old woman (100 kg actual body weight, 165 cm) is admitted to ICU with MRSA bacteremia from an infected central line. Her creatinine is 85 μmol/L (stable). She has been commenced on vancomycin with a loading dose of 2 g.

a) Describe the mechanism of action of vancomycin and why it is ineffective against Gram-negative bacteria (3 marks)

b) Explain the rationale for AUC-guided dosing rather than trough-based monitoring for vancomycin (3 marks)

c) Calculate an appropriate loading dose for this patient. Explain your reasoning. (3 marks)

d) Describe the methods available for calculating vancomycin AUC (3 marks)

e) List THREE risk factors for vancomycin-associated nephrotoxicity and how they should be managed (3 marks)

---

SAQ 2: Model Answer

a) Mechanism of action and Gram-negative inactivity (3 marks)

Mechanism of action (2 marks):

• Vancomycin binds to the terminal D-Ala-D-Ala dipeptide of lipid II (peptidoglycan precursor)
• This prevents:
  • "Transglycosylation: Polymerization of glycan chains"
  • "Transpeptidation: Cross-linking of peptide chains"
• Results in defective cell wall synthesis and bactericidal activity (slowly)

Gram-negative inactivity (1 mark):

• Vancomycin is a large glycopeptide molecule (molecular weight 1,449 Da)
• Too large to penetrate the outer membrane porins of Gram-negative bacteria
• Gram-positive bacteria lack outer membrane, allowing vancomycin access to cell wall synthesis machinery

b) Rationale for AUC-guided dosing (3 marks)

2020 ASHP/IDSA/SIDP guideline shift (1 mark):

• Previous practice: Target trough 15-20 mg/L as surrogate for AUC
• Current practice: Target AUC/MIC 400-600 mg.h/L (assuming MIC 1 mg/L by broth microdilution)

Limitations of trough-based monitoring (1 mark):

• Trough concentrations are poor surrogates for AUC
• Same trough can correspond to widely different AUCs depending on dosing interval and clearance
• Trough 15-20 mg/L frequently results in AUC greater than 600 mg.h/L

Benefits of AUC-guided dosing (1 mark):

• Better correlation with efficacy (AUC/MIC predicts clinical outcomes)
• Reduces nephrotoxicity by 30-50% (avoids excessive AUC greater than 600)
• More precise individualization of therapy

c) Loading dose calculation (3 marks)

Weight-based approach (1 mark):

• Loading dose: 25-35 mg/kg based on actual body weight
• This patient: 100 kg
• Dose range: 2,500-3,500 mg

Calculation (1 mark):

• Recommended: 25-30 mg/kg for serious MRSA infection
• 30 mg/kg × 100 kg = 3,000 mg
• Practical recommendation: 3,000 mg loading dose (3 g)

Rationale (1 mark):

• Given loading dose of 2 g (20 mg/kg) is suboptimal
• In severe infection with increased Vd (sepsis, obesity), higher loading achieves therapeutic concentrations faster
• Consider additional 1 g to reach adequate initial exposure
• Cap at 3,000-3,500 mg even in morbid obesity

d) Methods for calculating vancomycin AUC (3 marks) (1 mark each)

1. Bayesian software (preferred):

   • Uses population pharmacokinetic models (e.g., Goti, Moise-Broder, Udy ICU models)
   • Requires 1-2 drug levels (not necessarily at steady state)
   • Software examples: DoseMeRx, InsightRX, Precise-PK
   • Accounts for real-time changes in renal function
   • Provides probability of target attainment

2. Two-level pharmacokinetic equations (Sawchuk-Zaske):

   • Requires peak (1-2 hours post-infusion) and trough (pre-dose) at steady state
   • Calculate elimination rate constant (ke) from log-linear decay
   • Calculate Vd from peak concentration and dose
   • AUC₂₄ = Dose / CL (where CL = ke × Vd)
   • Limitation: Less accurate with fluctuating renal function

3. Trough-only equations (nomograms):

   • Estimate AUC from single trough using population-based equations
   • Less accurate than Bayesian or two-level methods
   • May be used if only trough available
   • Not recommended for serious infections

e) Risk factors for vancomycin-associated nephrotoxicity and management (3 marks) (1 mark each)

---

Viva Scenarios

Viva Scenario 1: Antibiotic Pharmacology in Septic Shock

Setting: Cross-table viva, 10 minutes

Examiner: "Tell me about the pharmacokinetic changes that affect antibiotic dosing in septic shock."

Candidate: "Septic shock causes profound alterations in pharmacokinetics that affect all aspects of ADME - absorption, distribution, metabolism, and elimination."

"Starting with distribution, the volume of distribution for hydrophilic antibiotics like beta-lactams, aminoglycosides, and vancomycin can increase by 2-3 fold due to capillary leak syndrome, third-spacing, and aggressive fluid resuscitation. This dilutes drug concentrations and may result in subtherapeutic peak levels."

"Regarding elimination, septic shock can cause either reduced or augmented clearance. Early sepsis with hyperdynamic circulation may cause augmented renal clearance with creatinine clearance exceeding 130 mL/min. This accelerates elimination of renally-cleared drugs. Conversely, shock with hypoperfusion causes acute kidney injury with reduced clearance."

"Protein binding is also affected. Hypoalbuminemia is common and increases the free fraction of highly protein-bound drugs like ceftriaxone and flucloxacillin. This may enhance tissue penetration but also accelerates clearance."

"Hepatic metabolism is generally reduced due to decreased hepatic blood flow and inflammatory cytokine effects on CYP450 enzymes."

---

Examiner: "A patient with septic shock is receiving piperacillin-tazobactam. How would you optimize the dosing?"

Candidate: "I would use a three-pronged approach: appropriate loading, optimized infusion strategy, and therapeutic drug monitoring if available."

"First, the loading dose. Given the increased volume of distribution, I would give a loading dose of 4.5 grams of piperacillin-tazobactam over 30 minutes to rapidly achieve therapeutic concentrations."

"Second, the infusion strategy. Piperacillin exhibits time-dependent killing, so efficacy depends on the duration above MIC. Standard intermittent dosing may not maintain adequate concentrations throughout the dosing interval, particularly with augmented renal clearance. I would use either extended infusion over 3-4 hours, or continuous infusion."

"For continuous infusion, after the loading dose, I would infuse 13.5-18 grams of piperacillin-tazobactam over 24 hours. This maintains 100% fT>MIC at steady state."

"Third, if beta-lactam TDM is available, I would target a trough concentration of 4-8 times the anticipated MIC to ensure a safety margin."

---

Examiner: "What is the evidence for extended or continuous infusion of beta-lactams?"

Candidate: "The main evidence comes from the BLING trials and several meta-analyses."

"The BLING-II trial was a multicenter RCT comparing continuous versus intermittent infusion of piperacillin-tazobactam or meropenem in severe sepsis. The primary outcome of 90-day survival was not significantly different, but there was a higher clinical cure rate of 56% versus 46% with continuous infusion."

"The BLING-III trial was a larger study with over 7,000 patients. Again, there was no significant difference in 90-day mortality, which was the primary outcome. However, continuous infusion was associated with reduced ICU duration and improved clinical cure as secondary outcomes."

"Meta-analyses have shown a modest mortality benefit with extended or continuous infusion, with an odds ratio around 0.74-0.85. The benefit appears greatest in patients with higher severity of illness, typically APACHE II scores greater than 20, and when treating pathogens with higher MICs."

"The interpretation is that while there may not be a clear mortality benefit in all patients, continuous infusion improves PK/PD target attainment and may improve clinical outcomes. It is particularly valuable in patients with septic shock, augmented renal clearance, or high-MIC pathogens."

---

Examiner: "How do you dose aminoglycosides in the ICU?"

Candidate: "Aminoglycosides exhibit concentration-dependent killing with a prolonged post-antibiotic effect, which informs the dosing strategy."

"I use once-daily, high-dose, extended-interval dosing. For gentamicin or tobramycin, I give 5-7 mg/kg actual body weight as a single daily dose. For amikacin, the dose is 15-25 mg/kg."

"The rationale is threefold. First, higher peak concentrations improve bacterial killing since efficacy correlates with Cmax/MIC ratio, with a target of 8-10. Second, the prolonged post-antibiotic effect means bacteria remain suppressed even after drug levels fall below MIC. Third, once-daily dosing allows trough concentrations to fall below toxic thresholds, reducing nephrotoxicity and ototoxicity."

"In the ICU, I am aware that the increased volume of distribution may result in lower than expected peak concentrations. I may need to use the higher end of the dose range, 7 mg/kg for gentamicin, to achieve adequate peaks."

"Therapeutic drug monitoring is essential. I check a peak level 30 minutes after completing the infusion, targeting 20-30 mg/L for gentamicin or 60-80 mg/L for amikacin. I check a trough level before the next dose, targeting less than 1 mg/L for gentamicin or less than 5 mg/L for amikacin. If the trough is elevated, I extend the dosing interval."

---

Examiner: "What are the toxicities of aminoglycosides and how do you monitor for them?"

Candidate: "The two major toxicities are nephrotoxicity and ototoxicity."

"Nephrotoxicity occurs in 10-25% of critically ill patients receiving aminoglycosides. The mechanism involves accumulation in proximal tubular cells, causing lysosomal dysfunction and tubular necrosis. Risk factors include prolonged therapy beyond 7 days, elevated trough concentrations, concurrent nephrotoxins, and pre-existing renal impairment."

"I monitor for nephrotoxicity by checking creatinine daily and targeting trough levels less than 1 mg/L. Once-daily dosing reduces nephrotoxicity compared to multiple-daily dosing by allowing drug to clear from renal tubular cells between doses."

"Ototoxicity affects both cochlear and vestibular function, causing hearing loss and vestibular symptoms like vertigo and ataxia. It is often irreversible. The mechanism involves damage to hair cells in the cochlea and vestibular apparatus. Risk factors include high cumulative dose, prolonged therapy, concurrent loop diuretics, and pre-existing hearing impairment."

"For ototoxicity monitoring, I recommend baseline and weekly audiometry if therapy is expected to exceed 5-7 days. I limit duration when possible and avoid concurrent loop diuretics if an alternative exists."

---

Viva Scenario 2: Vancomycin and Glycopeptide Pharmacology

Setting: Cross-table viva, 10 minutes

Examiner: "A patient with MRSA bacteremia is receiving vancomycin. Tell me about the current approach to vancomycin dosing and monitoring."

Candidate: "The approach to vancomycin dosing has evolved significantly with the 2020 consensus guidelines, which shifted from trough-based to AUC-based monitoring for serious MRSA infections."

"The current target is AUC/MIC of 400-600 mg.h/L, assuming an MIC of 1 mg/L by broth microdilution. This target is based on data showing that AUC/MIC below 400 is associated with treatment failure, while AUC above 600 mg.h/L increases the risk of nephrotoxicity."

"For dosing, I start with a loading dose of 25-35 mg/kg of actual body weight, typically 25-30 mg/kg for serious infections. This accounts for the increased volume of distribution in critical illness. In a typical 70 kg patient, this would be approximately 2 grams, but in a larger patient, I might give up to 3 grams, capping at 3-3.5 grams even in morbid obesity."

"For maintenance dosing, I typically start with 15-20 mg/kg every 8-12 hours, depending on renal function, and adjust based on AUC calculations."

---

Examiner: "How do you calculate the AUC?"

Candidate: "There are three main methods for calculating AUC."

"The preferred method is Bayesian software, such as DoseMeRx or InsightRX. These programs use population pharmacokinetic models validated in ICU patients, such as the Goti or Udy models. They require 1-2 drug levels, which don't necessarily need to be at steady state. The advantage is that they account for changing renal function and provide a probability of target attainment."

"The second method is the two-level pharmacokinetic approach using first-order equations, often called the Sawchuk-Zaske method. This requires a peak level 1-2 hours after infusion and a trough level immediately before the next dose, both at steady state. I calculate the elimination rate constant from the log-linear decay, estimate volume of distribution, and then calculate AUC as dose divided by clearance."

"The third method uses trough-only equations or nomograms to estimate AUC from a single trough measurement. This is less accurate but may be used when only a trough is available. It's not recommended for serious infections where precision is important."

---

Examiner: "This patient has a measured creatinine clearance of 160 mL/min. How does this affect your approach?"

Candidate: "A creatinine clearance of 160 mL/min indicates augmented renal clearance, which is defined as creatinine clearance greater than 130 mL/min per 1.73 m². This occurs in 20-65% of critically ill patients, particularly younger patients, those with sepsis in the hyperdynamic phase, trauma patients, and those receiving aggressive fluid resuscitation."

"The clinical implication is that standard vancomycin dosing will result in subtherapeutic concentrations. The drug is cleared faster, resulting in lower AUC and lower trough levels."

"For this patient, I would increase the maintenance dose significantly. Instead of 1 gram every 12 hours, I might need 1.5 grams every 8 hours or even 2 grams every 8 hours, potentially requiring 4-5 grams per day to achieve the target AUC of 400-600."

"Early and frequent therapeutic drug monitoring is essential. I would obtain levels after 2-3 doses and use Bayesian software to calculate AUC and guide dose adjustments. I would recheck levels every 2-3 days or whenever renal function changes."

"It's important to recognize that ARC is often a transient state. As the patient's illness evolves, they may develop AKI, requiring dose reduction. Daily creatinine monitoring and vigilance for this transition is important."

---

Examiner: "What are the alternatives to vancomycin for MRSA infections?"

Candidate: "Several alternatives exist depending on the site of infection."

"For MRSA bacteremia, daptomycin is an alternative. It has concentration-dependent killing and is dosed at 6-10 mg/kg once daily. Advantages include once-daily dosing and no nephrotoxicity. Limitations include inactivation by pulmonary surfactant, so it cannot be used for pneumonia, and it requires CPK monitoring for myopathy."

"For MRSA pneumonia, linezolid is preferred by some experts due to better lung penetration compared to vancomycin. It is equally effective in the ZEPHyR trial with some suggestion of superiority. The dose is 600 mg every 12 hours orally or intravenously. Toxicities include thrombocytopenia in 30-50% of ICU patients, and therapy should be limited to 14 days when possible."

"Ceftaroline is a fifth-generation cephalosporin with MRSA activity due to binding to PBP2a. It can be used for MRSA skin and soft tissue infections and pneumonia, though it is not first-line for bacteremia."

"Teicoplanin is another glycopeptide with MRSA activity. It has a longer half-life allowing once-daily dosing after loading, but requires higher troughs (15-30 mg/L) for serious infections and has similar mechanisms and resistance patterns to vancomycin."

---

Examiner: "Tell me about the mechanism of vancomycin-resistant Enterococcus."

Candidate: "Vancomycin resistance in Enterococcus occurs through modification of the D-Ala-D-Ala target to reduce vancomycin binding affinity."

"The most important phenotypes are VanA and VanB."

"VanA is the most common and clinically significant. It involves substitution of D-Ala-D-Ala with D-Ala-D-Lactate. This single amino acid change reduces vancomycin binding affinity by 1000-fold. VanA is inducible by vancomycin, plasmid-mediated, and confers high-level resistance with MIC greater than 64 mg/L. Importantly, VanA confers resistance to both vancomycin and teicoplanin."

"VanB also involves D-Ala-D-Lactate substitution but is induced only by vancomycin, not teicoplanin. It confers moderate to high-level vancomycin resistance but organisms remain teicoplanin-susceptible. However, teicoplanin is not commonly used for VRE infections in practice."

"VanC is intrinsic to E. gallinarum and E. casseliflavus. It involves D-Ala-D-Serine substitution and confers only low-level resistance. These organisms are not typically considered true VRE."

"Treatment options for VRE infections include linezolid, which is first-line, daptomycin for bacteremia, and tigecycline for intra-abdominal infections."

---

MCQ Practice Questions

Question 1:

Which pharmacokinetic/pharmacodynamic parameter BEST predicts efficacy for meropenem?

A. Peak concentration / MIC (Cmax/MIC) B. Area under the curve / MIC (AUC/MIC) C. Percentage of time free drug exceeds MIC (%fT>MIC) D. Post-antibiotic effect duration E. Minimum bactericidal concentration / MIC ratio

Answer: C

Explanation: Meropenem, like all beta-lactams, exhibits time-dependent killing. Efficacy correlates with the duration that free (unbound) drug concentration exceeds the MIC (%fT>MIC). For carbapenems, the target is typically 40-50% for bactericidal effect and 100% for optimal efficacy in severe infections. Options A and B describe concentration-dependent and AUC-dependent killing patterns seen with aminoglycosides and fluoroquinolones respectively.

---

Question 2:

A patient with severe sepsis has a measured creatinine clearance of 180 mL/min. Which statement is MOST accurate regarding antibiotic dosing?

A. Standard antibiotic doses will achieve adequate concentrations B. Antibiotic doses should be reduced to prevent toxicity C. Augmented renal clearance increases drug half-life D. Higher or more frequent doses of renally-cleared antibiotics may be needed E. Only lipophilic antibiotics are affected by this phenomenon

Answer: D

Explanation: A creatinine clearance of 180 mL/min indicates augmented renal clearance (ARC), defined as CrCl greater than 130 mL/min/1.73 m². This results in enhanced elimination of renally-cleared antibiotics (beta-lactams, vancomycin, aminoglycosides), leading to subtherapeutic concentrations with standard dosing. Higher doses or more frequent administration is typically required. Option A is incorrect as standard doses are often inadequate. Option B is incorrect as doses need to increase, not decrease. Option C is incorrect as ARC shortens half-life. Option E is incorrect as hydrophilic drugs are primarily affected.

---

Question 3:

According to the 2020 vancomycin consensus guidelines, what is the target AUC/MIC ratio for serious MRSA infections?

A. 200-300 mg.h/L B. 400-600 mg.h/L C. 600-800 mg.h/L D. Trough 15-20 mg/L E. Peak 40-60 mg/L

Answer: B

Explanation: The 2020 ASHP/IDSA/SIDP consensus guidelines shifted from trough-based to AUC-based monitoring, targeting AUC/MIC 400-600 mg.h/L (assuming MIC 1 mg/L by broth microdilution). AUC below 400 is associated with treatment failure; AUC above 600 increases nephrotoxicity risk. Option D represents the previous trough-based target, which is now considered a poor surrogate for AUC.

---

Question 4:

Which statement BEST describes the mechanism of beta-lactamase inhibitor avibactam?

A. It is a suicide inhibitor that undergoes irreversible hydrolysis B. It binds covalently to beta-lactamases but can be recycled without hydrolysis C. It inhibits Class B metallo-beta-lactamases D. It has intrinsic antibacterial activity against Acinetobacter E. It requires combination with a carbapenem for activity

Answer: B

Explanation: Avibactam is a diazabicyclooctane (non-beta-lactam) beta-lactamase inhibitor with a unique mechanism. It binds covalently to beta-lactamases but, unlike clavulanate or tazobactam, does NOT undergo hydrolysis. The bond is reversible, and avibactam can be recycled, making it a more efficient inhibitor. It inhibits Class A (including KPC carbapenemases), Class C (AmpC), and some Class D (OXA-48) beta-lactamases, but NOT Class B metallo-beta-lactamases (NDM). It is combined with ceftazidime, not a carbapenem. Sulbactam has intrinsic Acinetobacter activity, not avibactam.

---

Question 5:

A patient receiving linezolid for VRE bacteremia develops thrombocytopenia on day 10 of therapy. Which statement is CORRECT?

A. Thrombocytopenia is rare, occurring in less than 5% of ICU patients B. The mechanism is immune-mediated platelet destruction C. Platelet count typically recovers within 5-7 days of drug discontinuation D. Linezolid-induced thrombocytopenia is more common with shorter courses E. Switching to daptomycin will likely cause cross-reactive thrombocytopenia

Answer: C

Explanation: Linezolid-induced thrombocytopenia occurs in 30-50% of ICU patients (much higher than the general ward population), making option A incorrect. The mechanism is myelosuppression (bone marrow suppression affecting megakaryocytes), not immune-mediated (option B incorrect). The effect is dose and duration-dependent, more common with longer courses (option D incorrect). Platelet count typically recovers within 5-7 days of discontinuation. Daptomycin has a different mechanism with no cross-reactivity (option E incorrect).

---

---

References

Landmark Studies and Guidelines

1. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1-10. PMID: 9455502

2. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol. 2004;2(4):289-300. PMID: 15031728

3. EUCAST. MIC determination of non-fastidious and fastidious organisms. European Committee on Antimicrobial Susceptibility Testing. 2023.

4. Waxman DJ, Strominger JL. Penicillin-binding proteins and the mechanism of action of beta-lactam antibiotics. Annu Rev Biochem. 1983;52:825-869. PMID: 6351730

5. Sauvage E, Kerff F, Terrak M, Ayala JA, Charlier P. The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis. FEMS Microbiol Rev. 2008;32(2):234-258. PMID: 18266856

Beta-Lactams

6. Vardakas KZ, Voulgaris GL, Maliaros A, Samonis G, Falagas ME. Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials. Lancet Infect Dis. 2018;18(1):108-120. PMID: 29102324

7. Marshall WF, Blair JE. The cephalosporins. Mayo Clin Proc. 1999;74(2):187-195. PMID: 10069359

8. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18(4):657-686. PMID: 16223952

9. Patel IH, Chen S, Parsonnet M, et al. Pharmacokinetics of ceftriaxone in humans. Antimicrob Agents Chemother. 1981;20(5):634-641. PMID: 6275779

10. Payne LE, Gagnon DJ, Riker RR, et al. Cefepime-induced neurotoxicity: a systematic review. Crit Care. 2017;21(1):276. PMID: 29137682

11. Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. Antimicrob Agents Chemother. 2011;55(11):4943-4960. PMID: 21859938

12. Nicolau DP. Pharmacokinetic and pharmacodynamic properties of meropenem. Clin Infect Dis. 2008;47 Suppl 1:S32-40. PMID: 18713048

13. Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother. 2009;64(1):142-150. PMID: 19398460

14. Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev. 2010;23(1):160-201. PMID: 20065329

15. Ehmann DE, Jahić H, Ross PL, et al. Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. Proc Natl Acad Sci U S A. 2012;109(29):11663-11668. PMID: 22753474

PK/PD Optimization

16. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37(3):840-851. PMID: 19237886

17. Dhaese SAM, Thooft ADJ, Farkas A, et al. Early target attainment of continuous infusion piperacillin/tazobactam and meropenem in critically ill patients: a prospective observational study. J Crit Care. 2019;52:37-43. PMID: 30951981

18. Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14(6):498-509. PMID: 24768475

19. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother. 2005;55(5):601-607. PMID: 15772142

Aminoglycosides

20. Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. Aminoglycosides: activity and resistance. Antimicrob Agents Chemother. 1999;43(4):727-737. PMID: 10103173

21. Magnet S, Blanchard JS. Molecular insights into aminoglycoside action and resistance. Chem Rev. 2005;105(2):477-498. PMID: 15700953

22. Taccone FS, Laterre PF, Spapen H, et al. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care. 2010;14(2):R53. PMID: 20370906

23. Udy AA, Lipman J, Jarrett P, et al. Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance? Crit Care. 2015;19:28. PMID: 25632568

24. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995;39(3):650-655. PMID: 7793867

25. Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother. 1999;43(7):1549-1555. PMID: 10390201

26. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995;39(3):650-655. PMID: 7793867

27. Lopez-Novoa JM, Quiros Y, Vicente L, Morales AI, Lopez-Hernandez FJ. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int. 2011;79(1):33-45. PMID: 20861826

28. Selby NM, Shaw S, Woodier N, Fluck RJ, Kolhe NV. Gentamicin-associated acute kidney injury. QJM. 2009;102(12):873-880. PMID: 19820138

Vancomycin

29. Levine DP. Vancomycin: a history. Clin Infect Dis. 2006;42 Suppl 1:S5-12. PMID: 16323120

30. Courvalin P. Vancomycin resistance in gram-positive cocci. Clin Infect Dis. 2006;42 Suppl 1:S25-34. PMID: 16323116

31. Truong J, Levkovich BJ, Padiglione AA. Simple approach to improving vancomycin dosing in intensive care: a standardised loading dose results in earlier therapeutic levels. Intern Med J. 2012;42(1):23-29. PMID: 21118414

32. Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77(11):835-864. PMID: 32191793

33. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18-55. PMID: 21208910

34. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008;52(4):1330-1336. PMID: 18227177

35. van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 2013;57(2):734-744. PMID: 23165462

36. Luther MK, Timbrook TT, Caffrey AR, Dosa D, Lodise TP, LaPlante KL. Vancomycin plus piperacillin-tazobactam and acute kidney injury in adults: a systematic review and meta-analysis. Crit Care Med. 2018;46(1):12-20. PMID: 29088001

37. Udy AA, Varghese JM, Altukroni M, et al. Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest. 2012;142(1):30-39. PMID: 22194587

38. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49(2):71-87. PMID: 20067334

39. Roberts DM, Roberts JA, Roberts MS, et al. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit Care Med. 2012;40(5):1523-1528. PMID: 22511134

Fluoroquinolones

40. Hooper DC. Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin Infect Dis. 2001;32 Suppl 1:S9-S15. PMID: 11249823

41. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997;61(3):377-392. PMID: 9293187

42. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993;37(5):1073-1081. PMID: 8517694

43. Schentag JJ, Gilliland KK, Paladino JA. What have we learned from pharmacokinetic and pharmacodynamic theories? Clin Infect Dis. 2001;32 Suppl 1:S39-46. PMID: 11249827

44. FDA Drug Safety Communication. FDA updates warnings for fluoroquinolone antibiotics. U.S. Food and Drug Administration. 2016.

Macrolides

45. Piscitelli SC, Danziger LH, Rodvold KA. Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharm. 1992;11(2):137-152. PMID: 1739181

46. Zhanel GG, Dueck M, Hoban DJ, et al. Review of macrolides and ketolides: focus on respiratory tract infections. Drugs. 2001;61(4):443-498. PMID: 11324679

47. Tamaoki J. The effects of macrolides on inflammatory cells. Chest. 2004;125(2 Suppl):41S-50S. PMID: 14872000

48. Spyridaki A, Raftogiannis M, Antonopoulou A, et al. Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by Gram-negative bacteria: results from a randomized clinical study. Antimicrob Agents Chemother. 2012;56(7):3819-3825. PMID: 22564842

49. RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10274):605-612. PMID: 33545096

Linezolid

50. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med. 2003;138(2):135-142. PMID: 12529096

51. Livermore DM. Linezolid in vitro: mechanism and antibacterial spectrum. J Antimicrob Chemother. 2003;51 Suppl 2:ii9-16. PMID: 12730137

52. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis. 2012;54(5):621-629. PMID: 22247123

53. Cattaneo D, Orlando G, Cozzi V, et al. Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections. Int J Antimicrob Agents. 2013;41(6):586-589. PMID: 23578875

54. Natsumoto B, Yokota K, Omata F, Furukawa K. Risk factors for linezolid-associated thrombocytopenia in adult patients. Infection. 2014;42(6):1007-1012. PMID: 25139540

55. Falagas ME, Manta KG, Ntziora F, Vardakas KZ. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother. 2006;58(2):273-280. PMID: 16735429

Antifungals

56. Odds FC, Brown AJ, Gow NA. Antifungal agents: mechanisms of action. Trends Microbiol. 2003;11(6):272-279. PMID: 12823944

57. Brüggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 2009;48(10):1441-1458. PMID: 19361301

58. Denning DW. Echinocandin antifungal drugs. Lancet. 2003;362(9390):1142-1151. PMID: 14550704

59. Laniado-Laborín R, Cabrales-Vargas MN. Amphotericin B: side effects and toxicity. Rev Iberoam Micol. 2009;26(4):223-227. PMID: 19836985

Critical Illness PK

60. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37(3):840-851. PMID: 19237886

61. Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient--concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev. 2014;77:3-11. PMID: 25038549

62. Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet. 2010;49(1):1-16. PMID: 20000153

63. Udy AA, Baptista JP, Lim NL, et al. Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations. Crit Care Med. 2014;42(3):520-527. PMID: 24201175

64. Udy AA, Varghese JM, Altukroni M, et al. Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest. 2012;142(1):30-39. PMID: 22194587

DALI Study

65. Roberts JA, Paul SK, Akova M, et al. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014;58(8):1072-1083. PMID: 24429437

66. Roberts JA, Abdul-Aziz MH, Davis JS, et al. Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials. Am J Respir Crit Care Med. 2016;194(6):681-691. PMID: 26974879

Infusion Studies

67. Abdul-Aziz MH, Sulaiman H, Mat-Nor MB, et al. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intensive Care Med. 2016;42(10):1535-1545. PMID: 27695893

68. Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007;44(3):357-363. PMID: 17205441

69. Dulhunty JM, Roberts JA, Davis JS, et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis. 2013;56(2):236-244. PMID: 23074313

70. Dulhunty JM, Roberts JA, Davis JS, et al. A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. Am J Respir Crit Care Med. 2015;192(11):1298-1305. PMID: 26200166

71. Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis. 2013;56(2):272-282. PMID: 23074314

TDM

72. Wong G, Brinkman A, Benber RJ, et al. An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units. J Antimicrob Chemother. 2014;69(5):1416-1423. PMID: 24443514

73. Huttner A, Harbarth S, Hope WW, Lipman J, Roberts JA. Therapeutic drug monitoring of the β-lactam antibiotics: what is the evidence and which patients should we be using it for? J Antimicrob Chemother. 2015;70(12):3178-3183. PMID: 26260131

Australian Guidelines

74. Therapeutic Guidelines Limited. Antibiotic. Version 16. Melbourne: Therapeutic Guidelines Limited; 2019. (eTG Complete)

75. Australian Commission on Safety and Quality in Health Care. Antimicrobial Stewardship Clinical Care Standard. Sydney: ACSQHC; 2020.

---

Related Topics

Prerequisites

• [[Pharmacokinetics and Pharmacodynamics]]
• [[Renal Physiology]]
• [[Hepatic Physiology]]
• [[Microbiology Fundamentals]]

Related Basic Sciences

• [[Drug Metabolism]]
• [[Receptor Pharmacology]]
• [[Bacterial Resistance Mechanisms]]

Clinical Applications

• [[Sepsis and Septic Shock]]
• [[Hospital-Acquired Infections]]
• [[Antimicrobial Stewardship]]
• [[Fungal Infections in ICU]]
• [[Therapeutic Drug Monitoring]]
• [[CRRT Pharmacology]]